miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Alzheimer's disease (AD) is characterized by amyloid-β plaques, tau tangles, and synaptic loss.
• MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and are implicated in neurodegenerative diseases.
• miR-137, a brain-specific miRNA, has emerged as a significant factor in AD pathogenesis.

Purpose of the Study:

• To review the multifaceted roles of miR-137 in Alzheimer's disease.
• To explore miR-137's potential as a diagnostic biomarker and therapeutic target for AD.
• To consolidate evidence on miR-137's molecular mechanisms and translational potential in AD.

Main Methods:

• Literature review and synthesis of existing research on miR-137 in AD.
• Bioinformatic analysis to identify miR-137-regulated genes and networks in AD.
• Analysis of studies investigating circulating miR-137 levels in AD patients.

Main Results:

• miR-137 influences key AD pathologies including amyloid-β production, tau phosphorylation, synaptic plasticity, neuroinflammation, mitochondrial function, and oxidative stress.
• Circulating miR-137 levels show correlation with AD progression, suggesting diagnostic utility.
• Bioinformatic analyses reveal disrupted gene networks regulated by miR-137 in AD.

Conclusions:

• miR-137 is a critical regulator in Alzheimer's disease, affecting multiple pathological pathways.
• miR-137 holds significant promise as a non-invasive biomarker for AD diagnosis and a therapeutic target for neuroprotection.
• Further research into miR-137's mechanisms and therapeutic applications could revolutionize AD management.